


Appendix C, attached herewith.

REMARKS

Upon entry of the above amendment, claims 1-5, 7 and 10-11 will be pending in the captioned application. The amendments to the claims do not add any new matter within the meaning of 35 U.S.C. §132. Accordingly, the Examiner is respectfully requested to enter the above amendment before examination. If the Examiner has any questions regarding this submission, she is invited to telephone the undersigned attorney.

Respectfully submitted,
NATH & ASSOCIATES PLLC

By: 
Gary M. Nath
Registration No. 26,965
Sheldon M. McGee
Registration No. 50,454
Customer No. 34375


Date: March 24, 2006
NATH & ASSOCIATES PLLC
112 South West Street
Alexandria, VA 22314
(703)-548-6284

GMN/SMM\PA.doc

AP20 Rec'd PCT/PTO 24 MAR 2006
 Appendix A

Claim Amendments

1. (Currently amended) ~~Compounds~~ A compound of formula I



in which

- R1 is hydrogen or 1-4C-alkyl,
- R2 is hydrogen, halogen, hydroxyl, nitro, amino, 1-7C-alkyl, trifluoromethyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 1-4C-alkoxy, completely or predominantly fluorine-substituted 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkoxy, 1-4C-alkoxycarbonyl, mono- or di-1-4C-alkylaminocarbonyl, mono- or di-1-4C-alkylaminosulfonyl, 1-4C-alkylcarbonylamino, 1-4C-alkylsulfonylamino, phenyl, R21- and/or R211-substituted phenyl, phenyl-1-4C-alkyl, phenyl-1-4C-alkyl wherein the phenyl moiety is substituted by R22, phenyl-1-4C-alkoxy, pyridyl, pyridyl substituted by R23, pyridyl-1-4C-alkyl, or pyridyl-1-4C-

alkyl wherein the pyridyl moiety is substituted by R24,
in which

R21 is cyano, halogen, carboxyl, 1-4C-alkyl, 1-4C-alkoxy, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, 1-4C-alkoxycarbonyl, aminosulfonyl, mono- or di-1-4C-alkylaminosulfonyl, amino, mono- or di-1-4C-alkylamino, trifluoromethyl, hydroxyl, phenylsulfonylamino or phenyl-1-4C-alkoxy,

R211 is halogen or 1-4C-alkoxy,

R22 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

R23 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

R24 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

R3 is hydrogen, halogen, 1-4C-alkyl or 1-4C-alkoxy,

R4 is 1-4C-alkyl,

R11 is 1-4C-alkyl,

~~and the salts, the N-oxides and the salts of the N-oxides of these compounds~~ or a salt, N-oxide or a salt of an N-oxide thereof.

2. (Currently amended) ~~Compounds~~ The compound according to claim 1 in which

R1 is hydrogen or 1-4C-alkyl,

R2 is hydrogen,

R3 is hydrogen,

R4 is methyl,

R11 is 1-4C-alkyl,

~~and the salts, the N-oxides and the salts of the N-oxides~~
~~of these compounds~~ or a salt, N-oxide or a salt of an N-
oxide thereof.

3. (Currently amended) ~~Compounds~~ The compound according to
claim 1 in which
either

R1 is hydrogen,

R2 is hydrogen,

R3 is hydrogen,

R4 is methyl, and

R11 is methyl or ethyl,

or

R1 is methyl,

R2 is hydrogen,

R3 is hydrogen,

R4 is methyl, and

R11 is methyl,

~~and the salts, the N-oxides and the salts of the N-oxides~~
~~of these compounds~~ or a salt, N-oxide or a salt of an N-
oxide thereof.

4. (Currently amended) ~~Compounds~~ The compound of formula I
 according to claim 1 in which R4 is methyl, ~~and the salts,~~
~~the N-oxides and the salts of the N-oxides of these~~
~~compounds~~ or a salt, N-oxide or a salt of an N-oxide
thereof.

5. (Currently amended) ~~Compounds~~ The compound of formula I
 according to claim 1 in which R1 is hydrogen, R4 is methyl
 and R11 is methyl, ~~and the salts, the N-oxides and the~~
~~salts of the N-oxides of these compounds~~ or a salt, N-oxide
or a salt of an N-oxide thereof.

6. (Canceled)

7. (Currently amended) ~~Pharmaceutical compositions~~ A
pharmaceutical composition containing one or more compounds
 of formula I according to claim 1, or a pharmaceutically
acceptable salt, N-oxide or a salt of an N-oxide thereof,
 together with ~~the usual pharmaceutical auxiliaries and/or~~

~~excipients~~ a pharmaceutically suitable auxiliary and/or
excipient.

8. - 9. (Canceled)

10. (Currently amended) A method for treating ~~illnesses~~ a
chronic inflammatory disease of peripheral organs and the
central nervous system (CNS) in a patient comprising
administering to said patient a therapeutically effective
amount of a compound of formula I according to claim 1, or
a pharmaceutically acceptable salt, N-oxide or a salt of an
N-oxide thereof.

11. (Currently amended) A method for treating an acute
inflammatory ~~diseases~~ disease in a patient comprising
administering to said patient a therapeutically effective
amount of a compound of formula I according to claim 1, or
a pharmaceutically acceptable salt, N-oxide or a salt of an
N-oxide thereof.